Martin J. Czejka

Learn More
The potential for a pharmacokinetic interaction between epirubicin and the second-generation multidrug resistance modulating agent D-verapamil (DVPM) has been investigated in six patients with advanced colorectal cancer. Our results indicate that a significant interaction takes place. Enhanced distribution of epirubicin from the serum and altered(More)
AIM Capecitabine, a 5-fluorouracil prodrug, has been integrated into the management of multiple cancer types. In order to obtain information about plasma levels of capecitabine in patients who had drug intake at home during chemotherapy, a simple HPLC method for capecitabine monitoring has been developed and validated. PATIENTS AND METHODS Capecitabine(More)
Forty six patients received a topical application of a 0.3% norfloxacin (Zoroxin; MSD, Austria) solution into the lower fornix at different time intervals and frequencies before undergoing planned extracapsular cataract extraction. Aqueous humor was sampled at the beginning of surgery and assayed for the level of the antibiotic with high performance liquid(More)
b-subunit crucial for renal Cl reabsorption and inner ear Kþ secretion. Nature 2001; 414: 558–561 3. Jeck N, Reinalter SC, Henne T et al. Hypokalemic salt-losing tubulopathy with chronic renal failure and sensorineural deafness. Pediatrics 2001; 108: E5 4. Shalev H, Ohali M, Kachko L, Landau D. The neonatal variant of Bartter syndrome and deafness:(More)
BACKGROUND Irinotecan (CPT-11) in combination with 5-fluorouracil/folinic acid is used successfully for first-line treatment of metastatic colorectal cancer. Capecitabine (CCB) represents a very convenient alternative to 5-fluorouracil, either as single agent or in a combination of regimens acting synergistically and with the potential to further improve(More)
The pharmacokinetics of the antimetabolite 5-fluorouracil (5FU, CAS 51-21-8) were investigated under the influence of the biomodulating agents folinic acid (FA), FA combined with dipyridamole (DPM), DPM, interferon-alpha-2b (IFN), and IFN combined with DPM. IFN as well as IFN/DPM cause an enormous increase of the 5FU plasma concentrations resulting in a(More)
The binding of 5-fluorouracil (1) to erythrocytes and to serum proteins under in vitro conditions was investigated. The binding rate of 1 to erythrocytes is dose-independent and amounts from 16.8 to 31.7% (concentration range 1 to 20 micrograms/ml). The mean coefficient of partition for erythrocytes is 0.25 (+/- 0.03), no binding to ghosts was observed. 1(More)
The serum and red blood cell (RBCs) disposition of epirubicin (EPR) after intravenous bolus injection without and with coadministered quinine ( QUI) was investigated in patients undergoing a cyclic chemotherapy with EPR. QUI possesses a statistical significant influence on the EPR serum concentrations and, as a consequence, on the pharmacokinetic parameters(More)
The pharmacokinetic parameters of mitoxantrone in patients with liver metastasis after intra-arterial 2 h and 24 h infusion (dosage 12 mg/m2) were investigated. Peak plasma concentrations were 305±60 ng/ml at 2 h infusion and 244± 89 ng/ml at 24 h infusion. These peak plasma concentrations occurred at 0.9±0.8 h during 2 h infusion and 5.5±3.4 h during 24 h(More)